US Stock Insider Trading | PTC Therapeutics disclosed 7 insider transactions on February 20

K-LinePoet · 2026-02-21T12:22:25+00:00

Ptc Therapeutics recently disclosed multiple insider trades, with director Klein Matthew B. selling 7,371 shares on February 18th. Other executives also engaged in similar selling transactions. The company focuses on biopharmaceuticals, especially the treatment of rare diseases.

K-LinePoet

2026-02-21 12:22:25

Abstract generation in progress

On February 20, 2026, Ptc Therapeutics (PTCT) disclosed seven insider trading transactions. Director Klein Matthew B. sold 7,371 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Director	Klein Matthew B.	February 18, 2026	Sell	7,371	69.36	511,300
February 20, 2026	Executive	Almstead Neil Gregory	February 18, 2026	Sell	3,121	69.36	216,500
February 20, 2026	Executive	Utter Christine Marie	February 18, 2026	Sell	2,494	69.36	173,000
February 20, 2026	Executive	Golden Lee Scott	February 18, 2026	Sell	2,484	69.36	172,300
February 20, 2026	Executive	Pauwels Eric	February 18, 2026	Sell	3,019	69.36	209,400
February 20, 2026	Executive	Gravier Pierre	February 18, 2026	Sell	2,992	69.36	207,500
February 19, 2026	Executive	Boulding Mark Elliott	February 17, 2026	Sell	2	70.13	140.30
February 19, 2026	Executive	Boulding Mark Elliott	February 17, 2026	Sell	2,811	69.29	194,800
February 19, 2026	Executive	Boulding Mark Elliott	February 17, 2026	Buy	2,813	25.69	72,300
February 19, 2026	Executive	Boulding Mark Elliott	February 18, 2026	Sell	3,081	69.36	213,700

[Company Information]

Ptc Therapeutics, Inc. was incorporated on March 31, 1998, as a Delaware corporation. PTC Therapeutics is a biopharmaceutical company focused on oral medicines for post-transcriptional control processes, discovering and developing proprietary small molecule drugs. The company’s research and development programs target multiple therapeutic areas, with a particular focus on developing and commercializing treatments for orphan and ultra-orphan rare diseases. The lead candidate product is ataluren, which is used to treat a genetic disorder caused by a mutation known as nonsense mutation.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.